Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
Subscribe To Our Newsletter & Stay Updated